Alpha Cognition Inc. filings document the regulatory record of a British Columbia biopharmaceutical issuer with no-par-value common shares listed on Nasdaq under ACOG. The disclosures identify the company as an emerging growth company and cover formal reporting around ZUNVEYL commercialization, financial results, operational updates, and capital and compensation arrangements.
Recent Form 8-K filings address results of operations, Regulation FD disclosures, board appointments and departures, equity awards under incentive plans, and material agreements tied to legacy Memogain asset and license obligations. Proxy materials describe annual general meeting matters, including director elections, board size, auditor appointment, shareholder voting procedures, and accompanying annual financial statement materials.
Alpha Cognition Inc. entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC, allowing the company to sell common shares from time to time with an aggregate gross sales value of up to US$75.0 million. Under this arrangement, Wainwright will act as sales agent and use commercially reasonable efforts to execute sales based on the company’s instructions, earning a commission of up to 3.0% of the gross sales price of shares sold.
Sales may be conducted as at-the-market offerings on the Nasdaq Capital Market or through ordinary brokers’ transactions as permitted under Rule 415 of the Securities Act. Alpha Cognition is not obligated to sell any shares and may suspend or terminate the program at any time.
Alpha Cognition Inc. is registering securities on Form S-3 and discloses recent commercial, licensing and corporate developments. The company announced the commercial launch of ZUNVEYL (benzgalantamine) on March 19, 2025, a U.S.-approved treatment for mild-to-moderate Alzheimer’s disease. On January 8, 2025, Alpha Cognition entered an exclusive license with China Medical System Holdings Limited covering Asia (ex-Japan), Australia and New Zealand with aggregate deal terms of $44 million, including $6 million in upfront payments and eligibility for royalties; CMS will handle regulatory, development, manufacturing and commercialization in those territories. On January 14, 2025 the company made four strategic commercial and medical hires. As of August 22, 2025, several European, Canadian and Australian patents derived from WO2009127218 and WO2014016430 are abandoned or in the process of abandonment. Financial disclosure items include net tangible book value per share of $1.97 as of June 30, 2025, and material potential dilution from warrants, preferred conversions and options (multi-million share totals disclosed).
Alpha Cognition director Robert Wills purchased 15,000 shares of common stock in open market transactions on 08/18/2025. The filing shows a weighted average price of $8.4885 per share, with individual trade prices ranging from $8.15 to $8.86. After the purchases the reporting person beneficially owns 15,000 shares. The Form 4 was filed by one reporting person and identifies the purchase as an open market acquisition; the filer agrees to provide transaction-level price details on request.
Alpha Cognition director Phillip Joseph Mertz reported a sale of 27,778 common shares on 08/18/2025 at a reported price of $9 per share. After the transaction he beneficially owns 22,462 shares directly and 12,560 shares indirectly through Mertz Holdings. The Form 4 includes a standard disclaimer that the reporting person disclaims beneficial ownership except to the extent of pecuniary interest, and it is signed by Phillip Mertz on 08/20/2025.
Alpha Cognition director Leonard Powell Mertz reported an insider share purchase. On 08/18/2025, an entity described as The Len Mertz Trust bought 27,778 Alpha Cognition common shares in an open-market transaction at $9 per share.
After this trade, the trust held 121,503 common shares indirectly for Mertz, while he also reported 138,495 common shares held directly. This filing shows both his indirect holdings through the trust and his directly owned stake in Alpha Cognition Inc.